Vision impairment is one of the most pervasive disabilities on earth. It doesn’t have to be. 

Of the more than two billion people around the world who suffer from vision impairment or blindness, half of those cases could be successfully treated — if not prevented entirely. But there is a glaring gap between the number of people in need of sight-restoring surgery and the number of skilled ophthalmic surgeons available to perform it. This shortage is only projected to increase as fewer ophthalmic surgeons enter the field each year despite a continuous surge in demand for care. 

This is a clear example of an urgent, global problem that can only be solved by leveraging cutting-edge technology that allows us to do more with less. We can’t magically produce more ophthalmic surgeons around the world — but with robotics, we can effectively expand their reach. 

ForSight Robotics is delivering on this vision with a surgical robotics system to equip medical professionals with the tools and support to perform life-changing, sight-restoring cataract surgery. As one of the most commonly performed surgical procedures in the world (second only to blood draws in volume) even incremental improvement in cataract surgery could unlock meaningful improvement for millions of patients. But ForSight isn’t aiming for incremental gains; it’s building something fundamentally new. The company’s ORYOM™platform enables sub-micron precision and unlocks new levels of consistency and safety in cataract surgery. Eclipse is proud to be leading the company’s $125M Series B. Renowned physician Dr. Frederic Moll, widely known as the “father of surgical robotics,” also participated in the round along with Reiya Ventures and other existing investors. With the latest funding — which is one of the largest surgical robotics rounds to date — the company will continue development, scale-up, and clinical testing of ORYOM. 

ORYOM is a true surgical assistant, offering superhuman steadiness, control, and repeatability in a way that manual procedures can’t. Because the system can support telesurgery and remote operation, it opens up possibilities for radically expanding access in underserved regions where there simply aren’t enough skilled surgeons to meet demand. In markets like India and China, where hundreds of millions of patients are waiting for care, and where surgeon shortages are severe, this platform could be transformational.

Beyond the significant need, cataract surgery is uniquely well-suited for robotics intervention. The procedure demands incredibly fine movements and micron-level precision, which robotic systems are inherently designed to deliver. Moreover, the anatomy of the eye is remarkably consistent across patients, making it ideal for repeatable, standardized procedures — which establishes a clear clinical path for regulatory approval. 

ForSight is already well on its way, and has made enormous progress since Eclipse invested in the company’s Series A in 2022. Having completed hundreds of porcine-eye procedures and achieving critical safety certification, the company is set to begin human clinical trials later this year. They’ve built close partnerships with some of the most respected names in ophthalmology, including Dr. David Chang, and assembled a world-class advisory board including surgical robotics pioneer Dr. Moll and MAKO Surgical founder Rony Abovitz.

While the scale of the market opportunity is undeniable, what struck us most when we first visited ForSight’s headquarters in Israel wasn’t just the strength of the technology or its business case; it was the culture and the people. The founding team of Dr. Daniel Glozman, Dr. Joseph Nathan, and Professor Moshe Shoham brings together deep expertise in engineering, surgery, and commercialization. But more than that, they’ve built a team that’s united by purpose and resilience. In the face of incredibly difficult circumstances, including months where up to 20% of the team was working from shelters, they never lost focus. Their determination to deliver life-changing technology never wavered. It was, and continues to be, inspiring to witness.

This is the kind of company we love to work with: Mission-driven, built around world-class talent, and taking on a problem that truly matters. The eye care gap is growing wider by the year and ForSight has a realistic, clinically validated path to changing that, starting now.

Congratulations to Daniel, Joseph, and Moshe, and the entire ForSight team. This is more than a technological achievement — it’s an important step towards delivering on ForSight’s mission to  restore sight for millions of people around the world.

More on today's news from Forbes.

Follow Eclipse on LinkedIn or sign up for Eclipse’s Newsletter for the latest on building the New Economy.